HK1252958A1 - 單臂i型和ii型受體融合蛋白和其用途 - Google Patents

單臂i型和ii型受體融合蛋白和其用途

Info

Publication number
HK1252958A1
HK1252958A1 HK18112315.3A HK18112315A HK1252958A1 HK 1252958 A1 HK1252958 A1 HK 1252958A1 HK 18112315 A HK18112315 A HK 18112315A HK 1252958 A1 HK1252958 A1 HK 1252958A1
Authority
HK
Hong Kong
Prior art keywords
type
fusion proteins
receptor fusion
arm
arm type
Prior art date
Application number
HK18112315.3A
Other languages
English (en)
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of HK1252958A1 publication Critical patent/HK1252958A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112315.3A 2015-04-06 2018-09-26 單臂i型和ii型受體融合蛋白和其用途 HK1252958A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06
US201562259422P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
HK1252958A1 true HK1252958A1 (zh) 2019-06-06

Family

ID=57015654

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112315.3A HK1252958A1 (zh) 2015-04-06 2018-09-26 單臂i型和ii型受體融合蛋白和其用途

Country Status (21)

Country Link
US (3) US10358476B2 (zh)
EP (2) EP3865505A1 (zh)
JP (2) JP6810702B2 (zh)
KR (1) KR20170141215A (zh)
CN (3) CN107849114B (zh)
AU (2) AU2016246602B2 (zh)
CA (1) CA2981793A1 (zh)
CY (1) CY1124247T1 (zh)
DK (1) DK3280727T3 (zh)
ES (1) ES2864850T3 (zh)
HK (1) HK1252958A1 (zh)
HR (1) HRP20210411T1 (zh)
HU (1) HUE054180T2 (zh)
LT (1) LT3280727T (zh)
MA (1) MA53883A (zh)
MD (1) MD3280727T2 (zh)
PL (1) PL3280727T3 (zh)
PT (1) PT3280727T (zh)
RS (1) RS61728B1 (zh)
SI (1) SI3280727T1 (zh)
WO (1) WO2016164501A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
HUE054180T2 (hu) 2015-04-06 2021-08-30 Acceleron Pharma Inc Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
EP3828199A1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US20180086806A9 (en) * 2016-04-06 2018-03-29 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
WO2018067874A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
CA3039545A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
WO2018089706A2 (en) * 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP7246617B2 (ja) * 2017-02-01 2023-03-28 アクセルロン ファーマ インコーポレイテッド 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト
EP4241848A3 (en) * 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
AU2019206634A1 (en) 2018-01-12 2020-07-23 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
EP3749682A4 (en) * 2018-02-09 2021-11-17 Acceleron Pharma Inc. METHOD OF TREATMENT OF HETEROTOPIC OSSIFICATION
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
CA3147621A1 (en) * 2019-07-18 2021-01-21 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting tgf-.beta. signaling in cd4+ helper t cells for cancer immunotherapy
US20230190875A1 (en) * 2019-12-10 2023-06-22 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
AU2021236249A1 (en) * 2020-03-13 2022-10-06 Acceleron Pharma Inc. Single-arm ActRIIA and ActRIIB heteromultimers and methods for treating renal diseases or conditions
CN112190694B (zh) * 2020-09-17 2023-11-10 南通大学 细胞因子活化素c在治疗神经病理性疼痛方面的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ502795A (en) 1995-04-11 2001-09-28 Gen Hospital Corp Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
ATE437950T1 (de) 2003-09-15 2009-08-15 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
ES2372495T3 (es) * 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
AU2006318449B2 (en) 2005-11-23 2012-07-05 Acceleron Pharma Inc. Activin-actRIIa antagonists and uses for promoting bone growth
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
RU2559532C2 (ru) * 2006-11-02 2015-08-10 Акселерон Фарма, Инк. Антагонисты рецептора и лигандов alk1 и их применение
CA2677007A1 (en) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP2578684B1 (en) 2007-03-19 2016-02-24 National Research Council Of Canada Antagonists of ligands and uses thereof
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
WO2010031168A1 (en) 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
KR20190037355A (ko) * 2008-05-02 2019-04-05 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
CN107252486B (zh) * 2008-06-26 2021-10-22 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
MA32936B1 (fr) * 2008-11-26 2012-01-02 Amgen Inc Polypeptides de recepteur stabilises et leurs utilisations
EP2414043B1 (en) 2009-03-30 2016-01-13 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
ES2869864T3 (es) * 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
SI2831105T1 (en) 2012-03-28 2018-03-30 The Board Of Regents Of The University Of Texas System FUZIJA TGF TIPA II AND III RECEPTORS
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
WO2016090035A2 (en) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulators of activin and methods for modulating immune responses and t follicular helper cells
CA2980757A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
HUE054180T2 (hu) 2015-04-06 2021-08-30 Acceleron Pharma Inc Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
EP3828199A1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
PL3286206T3 (pl) 2015-04-22 2021-09-13 Biogen Ma Inc. Nowe hybrydowe białka pułapki na ligand actriib do leczenia chorób powodujących zanik mięśni
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
EP3344660A4 (en) 2015-08-31 2019-07-03 National Research Council of Canada TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
AU2017293778B2 (en) 2016-07-07 2022-03-24 Acceleron Pharma Inc. TGF-beta superfamily heteromultimers and uses thereof
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
EP3865505A1 (en) 2021-08-18
JP2018517664A (ja) 2018-07-05
US20220315642A1 (en) 2022-10-06
PL3280727T3 (pl) 2021-07-19
HUE054180T2 (hu) 2021-08-30
US10358476B2 (en) 2019-07-23
AU2016246602B2 (en) 2020-11-19
PT3280727T (pt) 2021-04-23
US20160289298A1 (en) 2016-10-06
US11208460B2 (en) 2021-12-28
JP6810702B2 (ja) 2021-01-06
CN113683708A (zh) 2021-11-23
AU2021200906B2 (en) 2023-04-06
SI3280727T1 (sl) 2021-07-30
CA2981793A1 (en) 2016-10-13
MD3280727T2 (ro) 2021-06-30
RS61728B1 (sr) 2021-05-31
US20200055920A1 (en) 2020-02-20
WO2016164501A1 (en) 2016-10-13
JP2021054839A (ja) 2021-04-08
LT3280727T (lt) 2021-04-12
CN107849114A (zh) 2018-03-27
AU2021200906A1 (en) 2021-03-04
ES2864850T3 (es) 2021-10-14
HRP20210411T1 (hr) 2021-04-30
EP3280727B1 (en) 2021-02-17
DK3280727T3 (da) 2021-03-15
EP3280727A1 (en) 2018-02-14
AU2016246602A1 (en) 2017-10-26
JP7203807B2 (ja) 2023-01-13
KR20170141215A (ko) 2017-12-22
MA53883A (fr) 2021-08-18
CN113683709A (zh) 2021-11-23
CY1124247T1 (el) 2022-07-22
CN107849114B (zh) 2021-08-20
EP3280727A4 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
HK1252958A1 (zh) 單臂i型和ii型受體融合蛋白和其用途
HK1250043A1 (zh) Gitrl融合蛋白及其用途
HK1244019A1 (zh) 融合蛋白
GB201509413D0 (en) Fusion protein
GB201504691D0 (en) Fusion protein
HRP20182029T1 (hr) Uti-fuzijski proteini
IL297395B1 (en) btla fusion protein agonists and uses thereof
ZA202003845B (en) Fusion proteins
HK1257937A1 (zh) 融合蛋白
GB201602850D0 (en) Fusion proteins
HK1251456A1 (zh) 免疫球蛋白融合蛋白及其用途
GB201713537D0 (en) Fusion Polypeptide
GB201503789D0 (en) Fusion polypeptide